

# Virtual Statistics Leaders Meeting 2020 – COVID-19 & Other Updates

---

**COVID-19:** What has changed since last time?

**U**PDATE

Do you have any other relevant **information** to share?

## COVID-19 ESIG Charter

<b>Responsibilities</b>	<ul style="list-style-type: none"> <li>• Provide a forum for sharing experiences of statistical and methodological issues relating to clinical trials impacted by COVID-19, clinical trials investigating new treatments for COVID-19 and diagnostic/antibody tests for COVID-19</li> </ul>		
<b>Accountability</b>	<ul style="list-style-type: none"> <li>• EFSPi Council / PSI Board</li> </ul>		
<b>Chair</b>	<ul style="list-style-type: none"> <li>• Chrissie Fletcher &amp; David Wright</li> </ul>		
<b>Members</b>	<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; border: none;">                     James Bell, BI                      Lars Endahl, Novo Nordisk                      Chrissie Fletcher, GSK                      Christine Hicking, Merck                      Achim Guettner, Novartis                      Khadija Rantell, MHRA                      Andrea Schulze, Bayer                      Tri Tat, CROS NT                      Marcel Wolbers, Roche                      David Wright, AstraZeneca                 </td> <td style="width: 50%; border: none;">                     Marie-Laure Casadebaig, BMS                      Thomas Jaki, University of Lancaster                 </td> </tr> </table>	James Bell, BI Lars Endahl, Novo Nordisk Chrissie Fletcher, GSK Christine Hicking, Merck Achim Guettner, Novartis Khadija Rantell, MHRA Andrea Schulze, Bayer Tri Tat, CROS NT Marcel Wolbers, Roche David Wright, AstraZeneca	Marie-Laure Casadebaig, BMS Thomas Jaki, University of Lancaster
James Bell, BI Lars Endahl, Novo Nordisk Chrissie Fletcher, GSK Christine Hicking, Merck Achim Guettner, Novartis Khadija Rantell, MHRA Andrea Schulze, Bayer Tri Tat, CROS NT Marcel Wolbers, Roche David Wright, AstraZeneca	Marie-Laure Casadebaig, BMS Thomas Jaki, University of Lancaster		
<b>Team &amp; Other Participants</b>	<ul style="list-style-type: none"> <li>• Representatives from EFSPi and local statistics associations, EFPIA, regulatory and academia</li> <li>• Collaborate with EFSPi/PSI regulatory committee on COVID-19 stats related regulatory guidance</li> <li>• Partner with the Vaccines ESIG on topics relating to COVID-19 vaccines.</li> </ul>		
<b>Format</b>	<ul style="list-style-type: none"> <li>• Monthly teleconferences</li> </ul>		
<b>Input required</b>	<ul style="list-style-type: none"> <li>• Sharing experiences</li> <li>• Discussing case studies</li> <li>• COVID-19 related publications, white papers, and regulatory guidance</li> </ul>		
<b>Deliverables</b>	<ul style="list-style-type: none"> <li>• Minutes of meetings</li> <li>• Collate and summarise publications, articles, presentations</li> <li>• Develop/highlight best practices and recommendations</li> <li>• Identify emerging news and trends</li> <li>• Collaborate with key stakeholder groups as appropriate</li> </ul>		



# Virtual Statistics Leaders Meeting 2020 – EFSPI Newsletter

---

Could you give us some *feedback* on the value of the monthly EFSPI newsletters?

# NEWSLETTER

We are looking for a small team of statisticians focusing on *communications* ...